Earlier work has suggested that familial Mediterranean fever, an inherited disorder characterized by sporadic episodes of inflammation involving the pleural and peritoneal cavities and the joints, is caused by the lack of a C5a inactivator normally found in serosal fluid. We have purified this inactivator from ascites fluid and obtained a protein of molecular weight 53 to 56 kD with a specific activity 10,000-fold greater EUTROPHILS ARE initially attracted to a site of inflammation by chemotactic factors, released first by the causative agent (eg, invading microorganisms) and then by the neutrophils themselves. A major chemotactic factor produced during inflammation is the complement fragment C5a, which is released not only through complement activation but also through the action of a protease released from neutrophil specific granules.'.' C5a-md1ated chemotaxis is thus a self-amplifying process in which low concentrations of C5a attract neutrophils to sites of inflammation, where higher local C5a concentrations provoke the release of the CS-splitting enzyme from the neutrophil-specific granules, resulting in the production of more C5a that attracts and activates more neutrophils. Because of self-amplification, the accidental release of even minimal amounts of C5a could cause an inappropriate fullscale inflammatory response, unless some countervailing mechanism existed to prevent such an occurrence.
EUTROPHILS ARE initially attracted to a site of inflammation by chemotactic factors, released first by the causative agent (eg, invading microorganisms) and then by the neutrophils themselves. A major chemotactic factor produced during inflammation is the complement fragment C5a, which is released not only through complement activation but also through the action of a protease released from neutrophil specific granules.'.' C5a-md1ated chemotaxis is thus a self-amplifying process in which low concentrations of C5a attract neutrophils to sites of inflammation, where higher local C5a concentrations provoke the release of the CS-splitting enzyme from the neutrophil-specific granules, resulting in the production of more C5a that attracts and activates more neutrophils. Because of self-amplification, the accidental release of even minimal amounts of C5a could cause an inappropriate fullscale inflammatory response, unless some countervailing mechanism existed to prevent such an occurrence.
In seeking such a countervailing mechanism, we discovered a diisopropyl fluorophosphate (Dm)-inhibitable enzyme in serosal fluids that neutralizes C5a, possibly by limited
The activity of this C5a inactivating enzyme was greatly reduced in serosal fluids from patients with familial Mediterranean fever (FMF), an inherited disease characterized by episodes of unprovoked inflammation involving serosal spaces.6-s These findings suggested that the C5a-inactivating enzyme functions to prevent inappropriate inflammation in serosal tissues and that its deficiency may explain the attacks of inflammation characteristic of FMF. In this report, we describe the purification of this enzyme from ascites fluid.
N MATERIALS AND METHODS

Materials
Recombinant C5a (rCSa), cytochalasin B, o-phenylenediamine, goat antirabbit IgG conjugated to alkaline phosphatase, p-nitroblue tetrazolium . HCI, 5-bromo-4-chloro-3-indolyl phosphate, benzamidine, Blue Sepharose CL-6B, and arginine agarose were purchased from Sigma (St Louis, MO). The rC5a was dissolved in distilled water containing bovine serum albumin (BSA) at 2.5 mg/mL. ['Z51]albumin (2.7 pCi/pg) was obtained from Amersham (Arlington Heights, IL). Freund's adjuvants were from Difco Lab (Detroit, MI). Diethyl aminoethyl (DEAE) cellulose (DE-52) was obtained from Whatman Biosystems (Maidstone, Kent, UK), Sephadex (3-10 and G-l00 from Pharmacia (Uppsala, Sweden), and nitrocellulose membranes from Schleicher and Schuell (Germany). All other chemicals were of reagent grade and were purchased from Sigma.
Methods
Assays of the CSa Inactivating Enzyme
Neutrophil chemotaxis. Chemotaxis was used to measure the C5a-inactivating enzyme in ascites fluid and (NH4)2S04 precipitates. Ascites fluid was heated at 56°C to inactivate complement;
(NH&S04 precipitates were dissolved in 10 mmoUL Tris . HC1 (pH 7.4) at an Azso of 6.6 and then desalted by dialysis against the same buffer. The C5a-inactivating enzyme in the samples was determined by measuring the chemotaxis of fresh human neutrophils as previously de~cribed,~ using a mixture of 10% (voYvol) sample and either 1% (voVvol) zymosan-activated serum or 1 nrnoVL rC5a as chemoattractant. Random migration was determined by measuring migration toward phosphate-buffered saline (PBS)/0.6% BSA/O.l% glucose. Chemotaxis was calculated by subtracting random migration from the distance traveled toward rC5a. Myeloperoxidase release. C5a-induced myeloperoxidase release from neutrophils' was used to locate the C5a-inactivating enzyme in column fractions. Fifty microliters of 10 nmoUL rC5a in suspending buffer (Hank's Balanced Salt Solution [HBSS] containing 25 mmoU L HEPES [pH 7.41 and 0.25% BSA) and an equal volume of the fraction to be assayed were loaded in triplicate into wells in a 96-well microtiter plate. The plate also contained a negative control consisting of 50 p L of suspending buffer plus 50 pL of column eluting buffer and a positive control containing 5 nmolL rC5a in the same buffer mixture used for the negative control. The plate was incubated at 37°C for the indicated period of time (usually 30 minutes). Twenty-five microliters of neutrophil suspension (4 X 10' celldmL in suspending buffer) that had been incubated for 10 minutes at 37°C with 5 pg/mL cytochalasin B (added from a stock solution containing 1 mg cytochalasin B/mL in dimethylsulfoxide) were added to each well, and degranulation was allowed to proceed for 10 minutes at 37°C. Myeloperoxidase release was then measured by adding to each well 50 pL sodium phosphate buffer, pH 6.8, followed by 25 pL of o-phenylenediamine/H,Oz solution (see below) and incubating for 5 to 20 minutes at room temperature, determining the incubation time by watching the color development in the positive control well. When the color in the positive control well had reached a satisfactory intensity, the reactions were stopped with 3 N HCl and A,,, was read in a microtiter plate reader. In conducting this assay, particular attention had to be paid to two points. First, neutrophil quality had to be optimum; the cells had to be as fresh as possible and completely free of clumps. Second, the o-phenylenediamine/H,02 solution had to be prepared just before use by dissolving a 10-mg o-phenylenediamine pill (Sigma) in 2.5 mL citrate-phosphate buffer (25.7 mL 0.2 mom NaZHPO, + 24.3 mL 0.1 m o m citric acid + 50 mL distilled water) and then adding to this solution 7.5 pL 30% HzOz (Sigma). Any delay between the preparation of the o-diphenyleneamine/H20z solution and its use resulted in an unsatisfactory assay. Results were corrected for myeloperoxidase release in the absence of rC5a.
Spectrophotometry. The inactivation of C5a by the C5a inactivator could be followed spectrophotometrically at 254 nm. Reaction mixtures containing various concentrations of rC5a together with 0.2-mL portions of purified inactivator in 1 mL of 10 mmol/L Tris * HC1, pH 7.4, were incubated at room temperature in a recording spectrophotometer. Rates were calculated from the differences in absorbance at 1 and 5 minutes. Figure 1 shows that a loss in absorbance of 0.01 U corresponds to the inactivation of 0.72 nmol C5dmL reaction volume. Loss of absorbance was not observed in incubations containing C5a alone, purified C5a inactivator alone, or a mixture of C5a and the inactivator together with 1 mmom phenylmethylsulfonyl fluoride (PMSF; PMSF experiment not shown). The spectrophotometric results were confirmed by chemotaxis measurements, which showed that no chemotactic activity remained after 15 minutes of incubation. HCV50 mmoVL dithiothreitol for 5 minutes. Cyanocobalamin was added as marker and the mixture was desalted over a 10-mL Sephadex G-25 column equilibrated with PBS, eluting with PBS, and collecting 0.5-mL fractions. "'I-containing fractions eluting before the marker were pooled and used as the proteolysis substrate. To measure proteolysis, inactivator at the concentrations indicated was added to 3.5 nmol of protein (C5a or denatured ['2sI]albumin) in 0.5 mL of PBS. Duplicate incubations were performed for 15 minutes at 37°C. Loss of C5a activity was measured by the myeloperoxidase assay. Proteolysis of albumin was measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)/autoradiography and by the release of trichloroacetic acid-soluble counts. SDS-PAGE was performed on 20-pL portions of the reaction mixtures using a 10% gel, and radioactive bands were detected by exposing the gel to Agfa XP 18/24 film (Curix, Mortsel. Belgium).
Nonspecific Proteolysis
Preparation of Polyclonal Antibody Against the C5a Inhibitor
Rabbits were immunized with 100 to 200 pg of purified C5a inactivator in 1 mL of complete Freund's adjuvant (0.25 mL in each footpad). The animals were boosted 2 weeks later by an identical procedure and then three more times by subcutaneous injections of 100 to 200 pg of C5a inactivator in 1 mL of incomplete Freund's adjuvant. Serum was collected 3 weeks after the last injection, decomplemented by heating at 56°C for 30 minutes, and then assayed for activity against the C5a inactivator using the chemotaxis and the myeloperoxidase methods.
Gel Electrophoresis and Western Blotting
SDS-PAGE was performed by the method of Laemmli"' using 12% running gels. The gels were stained with either Coomassie Blue or silver stain. Nondenaturing PAGE was performed under the same conditions except for the omission of SDS and dithiothreitol. For Western blotting, the proteins were transferred electrophoretically to a nitrocellulose membrane that was blocked for 2 hours at room temperature with PBS/5% BSA and then incubated for 1 hour at room temperature with a 1:lOO dilution of the rabbit antiserum. Bands were visualized with goat antirabbit IgG conjugated to alkaline phosphatase followed by treatment with a solution containing p-nitroblue tetrazolium HCl (0.33 mg/mL) and 5-bromo-4-chloro-3-indolyl phosphate (0.165 mg/mL)."
RESULTS
Purification of the C5a-Inactivating Enzyme
Some ascites fluids from patients with benign hepatic cirrhosis were found to contain the C5a inactivator at the concentration previously found in normal peritoneal fl~ids.~.'.' Because ascites can be obtained in liter amounts, we used this fluid as the source of the inactivator for purposes of purification.
Ascites was obtained from patients with alcoholic or posthepatic cirrhosis of the liver and assayed to make sure the inactivator was present in the material (the inactivator tended to be absent from ascites obtained from patients with hepatitis B or malignant ascites). Ascites that contained the inactivator was centrifuged (1,500g for 10 minutes at 4°C) to remove cells and debris and then divided into 50-mL aliquots and stored at -20°C until use. The purification was performed at 4°C.
The C5a inactivator was precipitated from 50 mL of peritoneal fluid by bringing the fluid to 35% saturation with (NH4)?S04. After 4 hours, the mixture was centrifuged (15,OOOg for 20 minutes) and the supernatant was discarded.
The pellet was suspended in 5 mL of 0.01 mom Tris-HC1 (pH 7.4) and desalted over a Sephadex G-l0 column (2. The experiments were performed as described in the text. All assay mixtures contained 3.3 nmol/L C5a except the assay mixture used with crude peritoneal fluid, which contained 1 nmol/L C5a. Because these assays were performed using C5a concentrations far below the K, of the enzyme, the specific activities are expressed as nmol C5a/ min/mg inactivator/nmol/L C5a.
25 cm) equilibrated with the same buffer. Fractions containing the C5a inactivator were then pooled and applied to a DEAE-cellulose column (DE-52, 3 X 6 cm) equilibrated with 0.01 mom Tris-HC1 (pH 7.4). The active material was eluted with 0.25 m o m NaCl in the same buffer, collecting 5-mL fractions (Fig 2A) . Fractions containing inhibitory activity were pooled, desalted over Sephadex G-10, adjusted to a final buffer composition of 0.05 m o m Tris HCl (pH 7.0)/0.1 m o m KCl, and applied to a Blue Sepharose CL-6B column (1.6 X 10 cm) equilibrated with the same buffer, eluting with the same buffer at 0.7 ml/min. The C5a inactivator eluted with the pass-through. Fractions containing the C5a inactivator were pooled, concentrated to 4 mL by ultrafiltration with a PM-l0 membrane (Amicon Corp, Lexington, MA), and applied to a Sephadex G-l00 column (1.5 X 48 cm) equilibrated with 0.04 m o m Tris * HCl (pH 7.4). The column was eluted at 0.3 mL/min with the same buffer, collecting 3-mL fractions (Fig 2B) . The active fractions* were analyzed by SDS-PAGE, and those with the fewest protein bands were pooled. The pooled active fractions were applied to an L-arginine agarose affinity column (1.2 X 22 cm) equilibrated with 0.04 m o m Tris HCl (pH 8.5). The inhibitor activity was eluted at 0.45 mL/min with the same buffer containing 0.2 m o m NaCl, and the fractions (3 mL each) with the highest specific activity were pooled ( Fig  2C) . For SDS-PAGE analysis, the purified inactivator was concentrated using a Speedvac concentrator (SVC 100H; Savant, Fanningdale, NY). The purification is summarized in Table 1 .
* C5a activity was also inhibited by certain high molecular weight fractions, suggesting either that some of the CSa-inactivating protease was associated with one or more high molecular weight proteins or that the preparation applied to the G-l00 column contained one or more additional C5a antagonists. Selection of the low molecular weight fractions from the G100 column was based on earlier gel filtration studies showing that the molecular weight of the C5a inacti- . The affinity-purified enzyme was essentially free of the impurities present in the material applied to the affinity column (Fig 3 left, lane A) . On immunoblots of both the preaffinity and postaffinity column material, an inhibitory antibody raised to the purified CSa inactivator (see below) recognized the inactivator as a 53-to 56-kD antigen (Fig 3, In earlier work, the CSa inactivator was found to inactivate A B
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CSa but not the chemotactic peptide F-met-leu-phe.' Later work showed that CSa inactivated by partially purified CSa inactivator ran on SDS-PAGE slightly more rapidly than C%.' Figure 4 shows that the same product was generated by the pure enzyme.' In addition, pure CSa inactivator, like the partially purified inactivator.' was inactivated by PMSF and inhibited by benzamidine, but was only slightly affected by pepstatin ( Table 2) . Taken together, these findings support the idea that the CSa inactivator is a serine protease that performs limited proteolysis on a well-defined group of substrates, although the possibility that it inactivates chemotac-
Arginine Column
tic peptides by catalyzing some other reaction involving an amide bond (eg, hydrolysis of a glutamine or asparagine to the corresponding acid or rearrangement of the peptide backbone) cannot be ruled out. To date, the group of substrates for the inactivator has been found to consist of two chemotactic peptides: CSa, released by complement activa-
Gel Filtration
Fig 3. SDS-PAGE of pooled Sephadex G-l00 fractions that were applied to the L-arginine agarose column (left) and pooled fractions from the L-arginine agarose column (the purified enzyme; right). Samples from the pooled fractions were subjected t o SDS-PAGE as described in Materials and Methods. Lane A, stained with Coomassie Blue; lane B, immunoblot using anti-C5a inactivator antiserum (see Materials and Methods). BSA (molecular weight, 67 kD) and ovalbumin (molecular weight, 43 kD) were used as standards.
Characterization of the C5a lnactivator
About 3 pg of pure CSa inactivator were obtained from SO mL of ascites. SDS-PAGE of this material showed a single major band at a molecular weight of S3 to 56 kD ( The specificity of the CSa inactivator was further examined using denatured ['"I]albumin. Whereas trypsin was able to degrade the labelled albumin to peptides (Fig S; the aggregated material at the top of the gel was particularly susceptible to tryptic digestion), the CSa inactivator could do neither, even though it completely inactivated a similar (in molar terms) quantity of CSa under the experimental conditions (Lw in the myeloperoxidase assay was 0.324 for the starting material, 0.106 for the inactivated CSa, and 0.138 for the CSa-free blank). The results therefore confirm that the CSainactivating enzyme is not a general protease.
An antiserum was raised in rabbits against the purified CSa inactivator. This antiserum recognized the 53-to 56-kD Protease inhibitors at the concentrations indicated were added to 30-pL portions of purified C5a inactivator (0.66 nmol/L). The mixtures were then incubated with 1 nmol/L rC5a (final volume, 300 pL) for 10 minutes at 37°C. Chemotaxis was then measured as described in Materials and Methods. At the concentrations used, the inhibitors had no effect on chemotaxis. Other protease inhibitors (EDTA, dimercaptopropanol, N-ethylmaleimide, and N-tosyl-L-phenylalanine chloromethyl ketone) could not be examined because of interference with chemotaxis. Chemotaxis was calculated as the distance travelled in response to rC5a minus random migration of 48.0 2 3.2 pm. Chemotaxis in response to rC5a in the absence of the C5a inactivator was 39.1 t 0.7 pm. Results are expressed as the mean t SE of three experiments. band on a Western blot of partially purified C5a inactivator (Fig 3) . whereas normal rabbit serum recognized nothing. The antiserum did not recognize the protein on a Western blot of unfractionated peritoneal fluid, presumably because the amount was too low to be detected. However, it did inhibit C5a inactivation by such fluids, whereas normal rabbit serum had little effect (Fig 6) . Treatment of normal peritoneal fluids with the antiserum reduced C5a inactivator activity to the levels found in peritoneal fluids from patients with FMF (Table 3) . Chemotaxis was measured as described in Materials and Methods, using as chemoattractant 1% (vol/vol) zymosan-activated serum in the presence and absence of 10% (vol/vol) of the fluid to be studied. The mixture was preincubated for 10 minutes at 37°C before addition to the Boyden chamber. These conditions were chosen to achieve intermediate levels of C5a inactivation. The antiserum and the nonimmune normal serum were heat-inactivated (56°C for 30 minutes), diluted 1:lOO with PES, and then incubated with an equal volume of the peritoneal fluid for 30 minutes at 37°C before the chemotaxis assay was performed. Random migration was 35.0 t 3.2 pm. Results are expressed as the mean 2 SE. N indicates the number of experiments, each using a different heat-inactivated peritoneal fluid.
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The kinetic behavior of the C5a inactivator was evaluated by the spectrophotometric assay, which allowed measurements to be made of initial rates of C5a inactivation. By this method, C5a inactivation was proportional to the inactivator concentration (Fig 7) . The purified inactivator obeyed saturation kinetics as the concentration of C5a was varied (Fig 8) , showing K,,, values for C5a of 3.6 and 3.2 ymol/L and V,,,,, values at 25°C of 60 and 46 nmol CSa/min/mg protein, respectively, in two separate experiments.
DISCUSSION
In defining the physiologic function of the C5a inactivator, its substrate specificity is a key consideration. Earlier experiments showed that even after inactivation by this enzyme, C5a was recognized by a polyclonal anti-C5a antibody.' This finding plus others discussed above strongly suggested that the range of substrates for this inactivator was narrow. Our experiments with [1251]albumin provide additional support for this idea and further suggest that the activity of the inactivator may be limited to C5a and possibly to a few other proteins containing sequences related to the sequence around the C5a cleavage site.
The C5a inactivator described here was found to be deficient in serosal fluids of patients with FMF, a disorder characterized by inappropriate attacks of inflammation. The clinical features of FMF suggest that the function of the CSa inactivator is to prevent the development of unprovoked inflammatory reactions by counteracting the effects of small amounts of C5a that may be accidentally released into the serosal At its concentration in peritoneal fluid (=S pg/mL, based on the peritoneal fluid protein concentration and the degree of purification needed to obtain homogeneous enzyme from unfractionated peritoneal fluid), the CSa inactivator will inactivate C5a released by such an accident with a half-time of about 2 minutes at 25°C (and probably an even shorter half-time at 37"C), a rate that would appear to be fast enough to prevent the C5a from provoking a full- scale inflammatory response. We postulate that the attacks typical of FMF occur because without the protection of the C5a inactivator, a bolus of C5a released accidentally into a serosal space will sometimes persist long enough to incite an inappropriate inflammatory reaction.
At some point it will be important to demonstrate in patients with FMF an abnormality of this C5a-inactivating protein at a molecular level. This demonstration could be accomplished by immunoblotting if the EMF mutation results in the loss of this protein or the production of a protein of abnormal size, and if an antibody becomes available that can detect the protein on a blot of normal unfractionated ascites. However, a missense mutation may only be detectable as a base replacement in a coding region of the gene encoding this protein. In principle, this could be determined by sequencing a cDNA from an FMF patient, but obtaining the mRNA needed for cloning such a cDNA will be extremely difficult. It is therefore likely that in patients with FMF, the detection of mutations in this protein will have to be performed by exon sequencing at the genomic level.
